Shanghai Aicobio Biopharmaceutical Technology

Shanghai Aicobio Biopharmaceutical Technology is a clinical-stage biotechnology company based in China, specializing in the discovery and development of innovative small molecule drugs for autoimmune diseases and oncology. The company focuses on the development of selective kinase inhibitors, particularly targeting the Janus kinase (JAK) family and various receptor tyrosine kinases. Its lead programs include selective JAK inhibitors designed to treat inflammatory conditions such as rheumatoid arthritis and atopic dermatitis with improved safety profiles. Aicobio leverages its internal R&D capabilities to advance a pipeline of candidates from early discovery through clinical proof-of-concept.